DIPK2A: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: DIPK2A

NCBI ID: G205428

DIPK2A

DIPK2A: A Potential Drug Target Or Biomarker for Various Diseases

DIPK2A, also known as DIPK2A variant 1, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The DIPK2A gene is located on chromosome 16 and encodes for a protein known as DIPK2, which is a key regulator of cell signaling pathways.

The DIPK2 gene has been implicated in the development and progression of numerous diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have shown that individuals with certain genetic variations in the DIPK2 gene are at an increased risk of developing neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, DIPK2A has also been identified as a potential biomarker for several diseases. For example, studies have shown that individuals with certain genetic variations in the DIPK2 gene are at an increased risk of developing certain types of cancer, such as breast cancer and lung cancer. Additionally, the DIPK2A gene has been shown to be involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

One of the reasons why DIPK2A has potential as a drug target is because it is involved in a wide range of cellular signaling pathways, including cell division, cell growth, and cell survival. Studies have shown that DIPK2 is involved in the regulation of several cellular processes that are critical for the growth and survival of cells, including cell division, cell growth, and cell survival.

In addition to its role in cellular signaling pathways, DIPK2 has also been shown to play a role in the regulation of cellular structure and function. For example, studies have shown that DIPK2 is involved in the regulation of the structure and function of the actin filament, which is a protein that is involved in the regulation of cell shape and movement.

DIPK2A variants have also been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have shown that individuals with certain genetic variations in the DIPK2 gene are at an increased risk of developing neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, the DIPK2A gene has been shown to be involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In conclusion, DIPK2A is a gene that has potential as a drug target or biomarker for the treatment of various diseases. Its involvement in cellular signaling pathways and its role in the regulation of cellular structure and function make it an attractive target for drug development. Further research is needed to fully understand the potential of DIPK2A as a drug and biomarker.

Protein Name: Divergent Protein Kinase Domain 2A

Functions: May play a role in cardiomyocyte proliferation through paracrine signaling and activation of the PPI3K-AKT-CDK7 signaling cascade

The "DIPK2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIPK2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets